10-Q: BiomX Inc. Reports Second Quarter 2024 Results, Highlights Progress in Clinical Programs

BiomX Inc. reported its financial results for the second quarter of 2024, showcasing advancements in its clinical programs and the impact of the Adaptive Phage Therapeutics acquisition.

Summary

• BiomX Inc. reported a net loss of $4.47 million for the three months ended June 30, 2024, compared to a net income of $6.41 million for the same period in 2023.
• The company's research and development expenses increased to $6.9 million for the quarter, up from $3.8 million in the prior year, due to increased clinical trial activities and the inclusion of Adaptive Phage Therapeutics (APT) operations.
• General and administrative expenses rose to $2.8 million, compared to $2.3 million in the same quarter of 2023, primarily due to the APT acquisition and increased professional services.
• Other income was $2.0 million for the quarter, a significant increase from $0.1 million in 2023, mainly due to the reversal of a contract liability related to a paused atopic dermatitis program.
• The company's interest expenses decreased to $14,000 from $745,000 in the prior year, due to the repayment of a loan in March 2024.
• BiomX recognized a gain of $11.8 million from the change in fair value of Private Placement Warrants.
• For the six months ended June 30, 2024, the net loss was $12.86 million, compared to a net loss of $12.77 million for the same period in 2023.
• The company's cash and cash equivalents totaled $31.6 million as of June 30, 2024, with management believing current funds will be sufficient to fund operations into the fourth quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical programs and a successful acquisition, the company is still operating at a loss, has a going concern warning, and faces significant risks. The sentiment is neutral to slightly negative.

Positives

• The acquisition of APT has expanded the company's pipeline and potential for growth.
• The company has made significant progress in its clinical programs for cystic fibrosis and diabetic foot osteomyelitis.
• The company has secured Fast Track and orphan drug designations for its cystic fibrosis treatment, which could expedite regulatory approval.
• The company has successfully raised capital through a private placement, strengthening its financial position.
• The company has reduced its debt burden by prepaying its long-term loan.
• The company has a clear timeline for upcoming clinical trial readouts.

Negatives

• The company reported a net loss for the quarter and six-month period.
• The company's operating expenses have increased due to the APT acquisition and ongoing clinical trials.
• The company has paused development of its atopic dermatitis program.
• The company is subject to the continued listing standards of the NYSE American and received a deficiency letter for not meeting minimum stockholders equity standards.
• The company has a going concern warning due to accumulated losses and negative cash flows.

Risks

• The company's ability to generate revenue and raise sufficient financing to meet working capital requirements is uncertain.
• The integration of APT's operations into the company may present challenges.
• The timing and cost associated with developing product candidates using phage technology are unpredictable.
• Political and economic instability in Israel, where the company has its headquarters, could affect its business.
• The company's ability to enroll patients in clinical trials and achieve anticipated development milestones is subject to risks.
• The company faces competition from similar technologies and products.
• The company's ability to maintain compliance with the continued listing standards of the NYSE American is uncertain.
• The company is subject to potential security breaches, including cybersecurity incidents.

Future Outlook

The company expects to continue to incur losses in the foreseeable future and plans to fund its operations through future issuances of equity or debt securities, loans, and grants. Management believes current funds will be sufficient to fund operations into the fourth quarter of 2025.

Management Comments

• Management believes current funds will be sufficient to fund its operations into the fourth quarter of 2025.
• Management believes that there is substantial doubt as to the Company's ability to continue as a going concern.

Industry Context

The company's focus on phage therapy aligns with the growing interest in alternative treatments for antibiotic-resistant infections. The acquisition of APT positions BiomX as a more significant player in the phage therapy space, with a broader pipeline and increased clinical capabilities. The company's programs target significant unmet medical needs in cystic fibrosis and diabetic foot osteomyelitis, which are areas of high interest for pharmaceutical development.

Comparison to Industry Standards

• BiomX's approach to phage therapy is comparable to other companies in the space, such as Armata Pharmaceuticals and Felix Biotechnology, which are also developing phage-based treatments for bacterial infections.
• The company's Phase 2 clinical trials for BX004 and BX211 are similar to the development stages of other companies in the field, with a focus on safety, tolerability, and efficacy.
• The company's financial results are typical for a clinical-stage biotechnology company, with significant R&D expenses and no current revenue generation.
• The company's cash runway into the fourth quarter of 2025 is a critical metric, and it will need to secure additional funding to continue its operations beyond that point.
• The company's focus on personalized phage therapy for DFO is a unique approach compared to some competitors that are focused on fixed cocktail therapies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The company's financial performance and stock price may be negatively impacted by the net loss and going concern warning. However, the acquisition of APT and progress in clinical programs could be seen as positive developments.
• Employees: The integration of APT's workforce may lead to changes in the company's structure and operations. The company's financial stability is important for job security.
• Customers: The company's clinical programs are aimed at developing treatments for unmet medical needs, which could benefit patients with cystic fibrosis and diabetic foot osteomyelitis.
• Suppliers: The company's financial stability is important for maintaining relationships with suppliers.
• Creditors: The company's ability to repay its debts is dependent on its financial performance and ability to raise additional capital.

Next Steps

• Initiate a Phase 2b study for BX004 in cystic fibrosis patients in the fourth quarter of 2024.
• Continue the Phase 2 study for BX211 in diabetic foot osteomyelitis patients.
• Monitor the results of the NIH study in cystic fibrosis.
• Seek additional funding to support ongoing operations and development activities.
• Monitor compliance with NYSE American listing standards.

Key Dates

Keywords

phage therapy, cystic fibrosis, diabetic foot osteomyelitis, clinical trials, bacteriophage, acquisition, biotechnology, FDA, BX004, BX211